Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

被引：0
作者：
Hojjat Ahmadzadehfar
Kambiz Rahbar
Richard P. Baum
Robert Seifert
Katharina Kessel
Martin Bögemann
Harshad R Kulkarni
Jingjing Zhang
Carolin Gerke
Rolf Fimmers
Clemens Kratochwil
Hendrik Rathke
Harun Ilhan
Johanna Maffey-Steffan
Mike Sathekge
Levent Kabasakal
Francisco Osvaldo Garcia-Perez
Kalevi Kairemo
Masha Maharaj
Diana Paez
Irene Virgolini
机构：
[1] University Hospital Bonn,Department of Nuclear Medicine
[2] Klinikum Westfalen,Department of Nuclear Medicine
[3] University Hospital Muenster,Department of Nuclear Medicine
[4] Zentralklinik Bad Berka,Center for Radiomolecular Precision Oncology
[5] University Hospital Münster,Department of Urology
[6] University of Bonn,Institute for Medical Biometry, Informatics and Epidemiology
[7] University Hospital Heidelberg,Department of Nuclear Medicine
[8] LMU,Department of Nuclear Medicine
[9] University Hospital Munich,Department of Nuclear Medicine
[10] Medical University Innsbruck,Department of Nuclear Medicine
[11] University of Pretoria & Steve Biko Academic Hospital,Department of Nuclear Medicine
[12] Istanbul University,Department of Nuclear Medicine and Molecular Imaging
[13] Instituto Nacional de Cancerología Mexico City,Department of Nuclear Medicine
[14] Docrates Cancer Center,Department of Nuclear Sciences and Applications
[15] Imaging and Therapy Centre,undefined
[16] Nuclear Medicine and Diagnostic Imaging Section,undefined
[17] IAEA,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2021年 / 48卷
关键词：
mCRPC; Radioligand therapy; Lu-PSMA; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：113 / 122
页数：9
相关论文
共 174 条
[11]  
Cordon-Cardo C(2019)Treatment outcome, toxicity, and predictive factors for Radioligand therapy with (177)Lu-PSMA-I&T in metastatic castration-resistant prostate cancer Eur Urol 75 920-962
[12]  
Tolkach Y(2019)Clinical outcomes of (177)Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy J Nucl Med 60 955-1454
[13]  
Gevensleben H(2017)Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617 Eur J Nucl Med Mol Imaging 44 1448-19
[14]  
Bundschuh R(2018)PSMA targeted radioligand therapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival Eur J Nucl Med Mol Imaging 45 12-1013
[15]  
Koyun A(2016)177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy J Nucl Med 57 1006-104S
[16]  
Huber D(2016)PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013 J Nucl Med 57 97S-55574
[17]  
Kehrer C(2017)Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride Oncotarget. 8 55567-246
[18]  
Bouchelouche K(2018)Delayed response after repeated (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer Eur J Nucl Med Mol Imaging 45 243-1670
[19]  
Choyke PL(2017)(177)Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer Eur J Nucl Med Mol Imaging 44 1663-99
[20]  
Capala J(2019)Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology Eur Urol 75 88-248
12345678910